| Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients. NCT07610733 Fudan University | Not yet recruiting | Phase 2 | June 1, 2026 |
| Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients NCT07460752 Mayo Clinic | Recruiting | Phase 2 | May 22, 2026 |
| Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. NCT07483658 CHU de Quebec-Universite Laval | Recruiting | N/A | May 13, 2026 |
| A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer NCT07287098 Eli Lilly and Company | Recruiting | Phase 2 | May 13, 2026 |
| Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin NCT07552493 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | N/A | May 1, 2026 |
| Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin NCT07552480 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | N/A | May 1, 2026 |
| Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin NCT07552506 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | N/A | May 1, 2026 |
| A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. NCT07450599 Bayer | Recruiting | Phase 2 | April 27, 2026 |
| Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study NCT07516704 Zhongda Hospital | Not yet recruiting | Early phase 1 | April 1, 2026 |
| Radiotherapy After Prostatectomy for Node Positive Prostate Cancer NCT07477626 Sun Yat-sen University | Recruiting | Phase 3 | March 20, 2026 |
| PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer NCT07460726 CancerCare Manitoba | Not yet recruiting | — | March 16, 2026 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response NCT07142551 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | Phase 2 | March 9, 2026 |
| Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) NCT07389187 Shanghai Changzheng Hospital | Not yet recruiting | Early phase 1 | Feb 2026 |
| Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer NCT07389174 Shanghai Changzheng Hospital | Not yet recruiting | Early phase 1 | Feb 2026 |
| Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial NCT07158021 University of Michigan Rogel Cancer Center | Recruiting | Phase 2 | January 22, 2026 |
| CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer NCT07268794 Fudan University | Not yet recruiting | Phase 2 | November 30, 2025 |
| Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER) NCT07313241 University of Texas Southwestern Medical Center | Recruiting | Phase 2 | November 14, 2025 |
| Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study NCT07179939 Fudan University | Not yet recruiting | Phase 2 | September 10, 2025 |
| The COSMYC Trial (COmbined Suppression of MYC) NCT06922318 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | Phase 2 | August 19, 2025 |
| Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients NCT06832774 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | Phase 2 | August 1, 2025 |
| Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer NCT07182279 The Methodist Hospital Research Institute | Recruiting | Phase 1, Phase 2 | August 1, 2025 |
| Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC NCT07172685 Qilu Hospital of Shandong University | Recruiting | N/A | July 30, 2025 |
| Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy NCT06953882 Yale University | Recruiting | Phase 2 | July 9, 2025 |
| Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery NCT06348134 University of Chicago | Recruiting | Phase 2 | March 18, 2025 |
| Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer NCT06291064 University of Chicago | Recruiting | Phase 2 | March 18, 2025 |
| Effect of a GnRH Analog on Hepatic Steatosis NCT06523530 Aristotle University Of Thessaloniki | Active, not recruiting | Phase 4 | November 26, 2024 |
| Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial) NCT06772441 German Oncology Center, Cyprus | Recruiting | Phase 2 | November 1, 2024 |
| A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer NCT07553988 R-Pharm International, LLC | Active, not recruiting | Phase 2 | October 24, 2024 |
| Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial) NCT06582446 German Oncology Center, Cyprus | Recruiting | Phase 2 | September 16, 2024 |
| Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients NCT06225284 National Taiwan University Hospital | Recruiting | Phase 2 | August 22, 2024 |
| Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) NCT06656624 The First Affiliated Hospital with Nanjing Medical University | Recruiting | Phase 2 | August 13, 2024 |
| Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer NCT06483386 Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | Phase 2 | July 15, 2024 |
| Adaptions and Resiliency to Multi-Stressor OpeRations NCT06455969 Bradley Nindl | Recruiting | Phase 4 | July 15, 2024 |
| Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer NCT06447623 Fudan University | Active, not recruiting | Phase 3 | June 11, 2024 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial NCT06378866 Mayo Clinic | Recruiting | Phase 2 | June 3, 2024 |
| Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer NCT06575257 Xijing Hospital | Recruiting | Phase 2 | May 1, 2024 |
| Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) NCT06387056 The First Affiliated Hospital of Xiamen University | Recruiting | Phase 2 | April 1, 2024 |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer NCT05827081 Novartis Pharmaceuticals | Active, not recruiting | Phase 3 | February 28, 2024 |
| Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers NCT06282588 Cancer Research Antwerp | Recruiting | Phase 2, Phase 3 | December 13, 2023 |
| Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC NCT06177015 The First Affiliated Hospital with Nanjing Medical University | Recruiting | Phase 3 | December 11, 2023 |